These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 8277195)

  • 1. The effects of high-dose recombinant soluble CD4 on human immunodeficiency virus type 1 viremia.
    Schacker T; Coombs RW; Collier AC; Zeh JE; Fox I; Alam J; Nelson K; Eggert E; Corey L
    J Infect Dis; 1994 Jan; 169(1):37-40. PubMed ID: 8277195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of high-dose, intravenous rsCD4 in subjects with advanced HIV-1 infection.
    Schacker T; Collier AC; Coombs R; Unadkat JD; Fox I; Alam J; Wang JP; Eggert E; Corey L
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Jun; 9(2):145-52. PubMed ID: 7749791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance of primary isolates of human immunodeficiency virus type 1 to neutralization by soluble CD4 is not due to lower affinity with the viral envelope glycoprotein gp120.
    Turner S; Tizard R; DeMarinis J; Pepinsky RB; Zullo J; Schooley R; Fisher R
    Proc Natl Acad Sci U S A; 1992 Feb; 89(4):1335-9. PubMed ID: 1741386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three-drug synergistic inhibition of HIV-1 replication in vitro by zidovudine, recombinant soluble CD4, and recombinant interferon-alpha A.
    Johnson VA; Barlow MA; Merrill DP; Chou TC; Hirsch MS
    J Infect Dis; 1990 Jun; 161(6):1059-67. PubMed ID: 2345291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial.
    Schooley RT; Merigan TC; Gaut P; Hirsch MS; Holodniy M; Flynn T; Liu S; Byington RE; Henochowicz S; Gubish E
    Ann Intern Med; 1990 Feb; 112(4):247-53. PubMed ID: 2297203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The V1/V2 region of human immunodeficiency virus type 1 modulates the sensitivity to neutralization by soluble CD4 and cellular tropism.
    Morikita T; Maeda Y; Fujii S; Matsushita S; Obaru K; Takatsuki K
    AIDS Res Hum Retroviruses; 1997 Oct; 13(15):1291-9. PubMed ID: 9339846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relative resistance of primary HIV-1 isolates to neutralization by soluble CD4.
    Daar ES; Ho DD
    Am J Med; 1991 Apr; 90(4A):22S-26S. PubMed ID: 2018048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of continuous-infusion soluble CD4 as a single agent and in combination with oral dideoxyinosine therapy in children with symptomatic human immunodeficiency virus infection.
    Husson RN; Chung Y; Mordenti J; Butler KM; Chen S; Duliege AM; Brouwers P; Jarosinski P; Mueller BU; Ammann A
    J Pediatr; 1992 Oct; 121(4):627-33. PubMed ID: 1357124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-level viremia in adults and children infected with human immunodeficiency virus: relation to disease stage and CD4+ lymphocyte levels.
    Saag MS; Crain MJ; Decker WD; Campbell-Hill S; Robinson S; Brown WE; Leuther M; Whitley RJ; Hahn BH; Shaw GM
    J Infect Dis; 1991 Jul; 164(1):72-80. PubMed ID: 1676046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current Status of CD4-Based Therapies for Prophylaxis and Treatment of HIV Infection.
    Sinclair JP; Shearer WT
    BioDrugs; 1997 Aug; 8(2):128-38. PubMed ID: 18020501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults.
    Jacobson JM; Lowy I; Fletcher CV; O'Neill TJ; Tran DN; Ketas TJ; Trkola A; Klotman ME; Maddon PJ; Olson WC; Israel RJ
    J Infect Dis; 2000 Jul; 182(1):326-9. PubMed ID: 10882617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma viremia as a sensitive indicator of the antiretroviral activity of L-697,661.
    Davey RT; Dewar RL; Reed GF; Vasudevachari MB; Polis MA; Kovacs JA; Falloon J; Walker RE; Masur H; Haneiwich SE
    Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5608-12. PubMed ID: 8516307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunization of simian immunodeficiency virus-infected rhesus monkeys with soluble human CD4 elicits an antiviral response.
    Watanabe M; Levine CG; Shen L; Fisher RA; Letvin NL
    Proc Natl Acad Sci U S A; 1991 Jun; 88(11):4616-20. PubMed ID: 2052546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Construction and characterization of a radio-iodinatable mutant of recombinant human CD4.
    Ferrer M; Godbout KL; Sullivan BJ; Austen DA; Sanderson CT; Kelley KC; Osburne MS; Harrison SC; van Schravendijk MR
    J Immunol Methods; 1997 Dec; 210(2):215-25. PubMed ID: 9520304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble human CD4 elicits an antibody response in rhesus monkeys that inhibits simian immunodeficiency virus replication.
    Watanabe M; Chen ZW; Tsubota H; Lord CI; Levine CG; Letvin NL
    Proc Natl Acad Sci U S A; 1991 Jan; 88(1):120-4. PubMed ID: 1986356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continued production of drug-sensitive human immunodeficiency virus type 1 in children on combination antiretroviral therapy who have undetectable viral loads.
    Persaud D; Siberry GK; Ahonkhai A; Kajdas J; Monie D; Hutton N; Watson DC; Quinn TC; Ray SC; Siliciano RF
    J Virol; 2004 Jan; 78(2):968-79. PubMed ID: 14694128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates.
    Daar ES; Li XL; Moudgil T; Ho DD
    Proc Natl Acad Sci U S A; 1990 Sep; 87(17):6574-8. PubMed ID: 2395859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells.
    Bailey JR; Sedaghat AR; Kieffer T; Brennan T; Lee PK; Wind-Rotolo M; Haggerty CM; Kamireddi AR; Liu Y; Lee J; Persaud D; Gallant JE; Cofrancesco J; Quinn TC; Wilke CO; Ray SC; Siliciano JD; Nettles RE; Siliciano RF
    J Virol; 2006 Jul; 80(13):6441-57. PubMed ID: 16775332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel assay allows genotyping of the latent reservoir for human immunodeficiency virus type 1 in the resting CD4+ T cells of viremic patients.
    Monie D; Simmons RP; Nettles RE; Kieffer TL; Zhou Y; Zhang H; Karmon S; Ingersoll R; Chadwick K; Zhang H; Margolick JB; Quinn TC; Ray SC; Wind-Rotolo M; Miller M; Persaud D; Siliciano RF
    J Virol; 2005 Apr; 79(8):5185-202. PubMed ID: 15795302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship between T cell proliferative responses and plasma viremia during treatment of human immunodeficiency virus type 1 infection with combination antiretroviral therapy.
    Binley JM; Schiller DS; Ortiz GM; Hurley A; Nixon DF; Markowitz MM; Moore JP
    J Infect Dis; 2000 Apr; 181(4):1249-63. PubMed ID: 10762561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.